[go: up one dir, main page]

MX2019000547A - Formulaciones de adamts13 liquidas y liofilizadas, estabilizadas. - Google Patents

Formulaciones de adamts13 liquidas y liofilizadas, estabilizadas.

Info

Publication number
MX2019000547A
MX2019000547A MX2019000547A MX2019000547A MX2019000547A MX 2019000547 A MX2019000547 A MX 2019000547A MX 2019000547 A MX2019000547 A MX 2019000547A MX 2019000547 A MX2019000547 A MX 2019000547A MX 2019000547 A MX2019000547 A MX 2019000547A
Authority
MX
Mexico
Prior art keywords
adamts13
lyophilized
formulations
liquid
stabilized formulations
Prior art date
Application number
MX2019000547A
Other languages
English (en)
Inventor
Hans-Peter Schwarz
H Peter Matthiessen
Peter L Turecek
Original Assignee
Takeda Pharmaceuticals Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceuticals Co filed Critical Takeda Pharmaceuticals Co
Publication of MX2019000547A publication Critical patent/MX2019000547A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24087—ADAMTS13 endopeptidase (3.4.24.87)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Dispersion Chemistry (AREA)
  • Dermatology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invención se refiere a formulaciones de ADAMTS13 con propiedades mejoradas o deseables. Como tal, la invención proporciona formulaciones líquidas y liofilizadas de ADAMTS13 que son adecuadas para administración farmacéutica. Entre otros aspectos, la invención también proporciona métodos para tratar varias enfermedades y condiciones relacionadas con el VWF y/o la disfunción de ADAMTS13 en un sujeto. También se proporcionan en la presente kits que comprenden formulaciones de ADAMTS13 útiles para el tratamiento de varias enfermedades y condiciones.
MX2019000547A 2009-09-21 2012-03-21 Formulaciones de adamts13 liquidas y liofilizadas, estabilizadas. MX2019000547A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US24435309P 2009-09-21 2009-09-21

Publications (1)

Publication Number Publication Date
MX2019000547A true MX2019000547A (es) 2020-11-12

Family

ID=43598388

Family Applications (3)

Application Number Title Priority Date Filing Date
MX2016005314A MX362382B (es) 2009-09-21 2010-09-21 Formulaciones de adamts13 liquidas y liofilizadas, estabilizadas.
MX2012003414A MX339205B (es) 2009-09-21 2010-09-21 Formulaciones de adamts13 liquidas y liofilizadas, estabilizadas.
MX2019000547A MX2019000547A (es) 2009-09-21 2012-03-21 Formulaciones de adamts13 liquidas y liofilizadas, estabilizadas.

Family Applications Before (2)

Application Number Title Priority Date Filing Date
MX2016005314A MX362382B (es) 2009-09-21 2010-09-21 Formulaciones de adamts13 liquidas y liofilizadas, estabilizadas.
MX2012003414A MX339205B (es) 2009-09-21 2010-09-21 Formulaciones de adamts13 liquidas y liofilizadas, estabilizadas.

Country Status (21)

Country Link
US (9) US8623352B2 (es)
EP (5) EP4218797B9 (es)
JP (2) JP5819303B2 (es)
KR (6) KR101891646B1 (es)
CN (2) CN102573792B (es)
AU (1) AU2010295299B2 (es)
BR (1) BR112012006283B1 (es)
CA (1) CA2774556A1 (es)
DK (4) DK3167897T3 (es)
EA (1) EA024267B1 (es)
ES (4) ES2579906T3 (es)
FI (2) FI3834841T3 (es)
FR (1) FR24C1049I1 (es)
HR (1) HRP20160295T1 (es)
HU (1) HUE028688T2 (es)
IN (1) IN2012DN02645A (es)
MX (3) MX362382B (es)
NZ (1) NZ598839A (es)
PL (4) PL4218797T3 (es)
PT (2) PT3834841T (es)
WO (1) WO2011035335A2 (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8415114B2 (en) 2008-12-05 2013-04-09 Baxter International Inc. Methods of measuring ADAMTS13-mediated in vivo cleavage of von Willebrand factor and uses thereof
HUE028688T2 (en) * 2009-09-21 2017-01-30 Baxalta GmbH Stabilized liquid and lyophilized adamts13 formulations
EP3311847A1 (en) * 2012-02-16 2018-04-25 Atyr Pharma, Inc. Histidyl-trna synthetases for treating autoimmune and inflammatory diseases
CN103566362B (zh) * 2012-07-21 2015-07-29 复旦大学 重组adamts13在制备脑出血药物中的用途
CA2890848C (en) * 2012-11-09 2020-11-17 Puget Sound Blood Center Protein stabilizing factors apolipoprotein a-1 or high density lipoprotein
AU2013203062C1 (en) * 2013-03-15 2018-06-28 Takeda Pharmaceutical Company Limited Subcutaneous administration of adamts13
DK2970921T3 (en) 2013-03-15 2019-01-14 Atyr Pharma Inc Histidyl-tRNA synthetase-Fc conjugates
CA2952609A1 (en) * 2014-06-26 2015-12-30 Amgen Inc. Solid protein formulations comprising stabilizer, sugar alcohol, sugar and surfactant
GB201510870D0 (en) * 2015-05-26 2015-08-05 Baxalta Inc And Katholieke Universiteit Leuven And Baxalta Gmbh Treatment of infarction
ES2983978T3 (es) * 2016-01-08 2024-10-28 Univ Kyoto Medicina que comprende ADAMTS13 como ingrediente principal
CN109789192B (zh) * 2016-08-04 2023-04-07 武田药品工业株式会社 使用adamts13治疗、改善和/或预防镰状细胞病、急性肺损伤和/或急性呼吸窘迫综合征中的血管阻塞危象
IL266264B2 (en) 2016-11-04 2023-11-01 Baxalta Inc Adeno-associated virus formulations
JP7679175B2 (ja) 2017-04-20 2025-05-19 エータイアー ファーマ， インコーポレイテッド 肺の炎症を治療するための組成物および方法
TWI810196B (zh) * 2017-07-25 2023-08-01 大陸商江蘇恆瑞醫藥股份有限公司 一種il-15蛋白質複合物醫藥組成物及其用途
JP2021532071A (ja) * 2018-07-11 2021-11-25 バクスアルタ インコーポレイテッド Ａａｖ組成物
EP4037704A4 (en) 2019-10-04 2023-04-26 The Children's Medical Center Corporation Adamts13 treatment to enhance graft survival
JP2023521658A (ja) 2020-04-02 2023-05-25 武田薬品工業株式会社 Ａｄａｍｔｓ１３バリアント、組成物、及びその使用
WO2021234458A1 (en) 2020-05-22 2021-11-25 Takeda Pharmaceutical Company Limited Adamts13 compositions and methods for treating and diagnosing complications of coronavirus disease
IL300596A (en) * 2020-08-13 2023-04-01 Hadasit Medical Res Services & Development Limited Mutants of disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13 (adamts-13), preparations and their uses in therapeutic methods
IL315475A (en) 2022-03-08 2024-11-01 Equashield Medical Ltd A position for transferring liquids in a robotic system for preparing medicines
KR20240112755A (ko) * 2023-01-11 2024-07-19 주식회사 녹십자 혈전성 질환의 예방 또는 치료를 위한 신규한 액상 제형물

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4797368A (en) 1985-03-15 1989-01-10 The United States Of America As Represented By The Department Of Health And Human Services Adeno-associated virus as eukaryotic expression vector
US5139941A (en) 1985-10-31 1992-08-18 University Of Florida Research Foundation, Inc. AAV transduction vectors
US5250421A (en) 1986-01-03 1993-10-05 Genetics Institute, Inc. Method for producing factor VIII:C-type proteins
US6013516A (en) 1995-10-06 2000-01-11 The Salk Institute For Biological Studies Vector and method of use for nucleic acid delivery to non-dividing cells
US5804420A (en) 1997-04-18 1998-09-08 Bayer Corporation Preparation of recombinant Factor VIII in a protein free medium
AT407255B (de) 1997-06-20 2001-02-26 Immuno Ag Rekombinanter zellklon mit erhöhter stabilität in serum- und proteinfreiem medium und verfahren zur gewinnung des stabilen zellklons
US6475725B1 (en) 1997-06-20 2002-11-05 Baxter Aktiengesellschaft Recombinant cell clones having increased stability and methods of making and using the same
US5994136A (en) 1997-12-12 1999-11-30 Cell Genesys, Inc. Method and means for producing high titer, safe, recombinant lentivirus vectors
ATE365052T1 (de) 1999-02-22 2007-07-15 Univ Connecticut Neue albuminfreie faktor viii formulierungen
JP2001227510A (ja) 2000-02-15 2001-08-24 Tomoe Tech Res Co 複作動型の空気式アクチュエータ
JP3783507B2 (ja) 2000-02-16 2006-06-07 日本精工株式会社 トロイダル型無段変速機用ディスクの加工方法
US6926894B2 (en) 2000-11-22 2005-08-09 Baxter Aktiengesellschaft Composition exhibiting a von willebrand factor (vWF) protease activity comprising a polypeptide chain with the amino acid sequence AAGGILHLELLV
JP2003284570A (ja) 2001-04-25 2003-10-07 Chemo Sero Therapeut Res Inst フォンビルブラント因子（ｖＷＦ）切断酵素
AU2002336367A1 (en) 2001-08-16 2003-03-03 The Regents Of The University Of Michigan Adamts13 genes and proteins and variants, and uses thereof
ITPR20010055A1 (it) 2001-08-31 2003-03-03 Vetroarredo Spa Procedimento e impianto per la realizzazione di mattoni in vetro.
KR100472006B1 (ko) 2002-10-09 2005-03-10 동부아남반도체 주식회사 모스 트랜지스터 제조 방법
US7780831B2 (en) * 2003-07-07 2010-08-24 The University Of North Carolina At Chapel Hill Assays for detection of von willebrand factor (vWF) multimers and for degradation of vWF by agents such as ADAMTS13 and related methods
GB0404693D0 (en) * 2004-03-02 2004-04-07 Univ London Pharmaceutical preparations for the treatment of ocular surface and other disorders
US20060094104A1 (en) 2004-10-29 2006-05-04 Leopold Grillberger Animal protein-free media for cultivation of cells
WO2006133955A1 (en) * 2005-06-17 2006-12-21 Baxter International Inc. Adamts13-comprising compositions having thrombolytic activity
JP4880997B2 (ja) * 2005-12-28 2012-02-22 アルフレッサファーマ株式会社 Ａｄａｍｔｓ１３の安定化方法
ES2629304T3 (es) 2006-01-04 2017-08-08 Baxalta Incorporated Medio de cultivo celular sin oligopéptidos
HUE028688T2 (en) * 2009-09-21 2017-01-30 Baxalta GmbH Stabilized liquid and lyophilized adamts13 formulations
US8823352B2 (en) 2011-07-11 2014-09-02 Linear Technology Corporation Switching power supply having separate AC and DC current sensing paths

Also Published As

Publication number Publication date
US11564979B2 (en) 2023-01-31
KR20250008986A (ko) 2025-01-16
EA024267B1 (ru) 2016-09-30
CN104224705A (zh) 2014-12-24
EP3167897B1 (en) 2021-01-27
MX2012003414A (es) 2012-06-19
CN104224705B (zh) 2018-02-02
KR20220139456A (ko) 2022-10-14
FI3834841T3 (fi) 2023-06-05
EP4218797B9 (en) 2025-04-30
EP4218797B1 (en) 2024-09-11
KR20190137954A (ko) 2019-12-11
EP2480198A2 (en) 2012-08-01
JP2013505270A (ja) 2013-02-14
HK1173968A1 (zh) 2013-05-31
HRP20160295T1 (hr) 2016-05-20
CN102573792A (zh) 2012-07-11
PL4218797T3 (pl) 2025-02-10
EP4467160A3 (en) 2025-01-15
EP3834841A1 (en) 2021-06-16
KR20120099646A (ko) 2012-09-11
WO2011035335A2 (en) 2011-03-24
PL2480198T3 (pl) 2016-09-30
PL3167897T3 (pl) 2021-09-27
US20140178357A1 (en) 2014-06-26
US20250099559A1 (en) 2025-03-27
US20170112906A1 (en) 2017-04-27
EP2480198B9 (en) 2016-11-23
IN2012DN02645A (es) 2015-09-11
US20110229455A1 (en) 2011-09-22
ES2579906T3 (es) 2016-08-17
ES2948612T3 (es) 2023-09-14
US10758599B2 (en) 2020-09-01
AU2010295299A1 (en) 2012-04-12
EP4218797A1 (en) 2023-08-02
BR112012006283A2 (pt) 2016-05-31
JP2015063556A (ja) 2015-04-09
PT4218797T (pt) 2024-12-09
PL3834841T3 (pl) 2023-07-24
MX362382B (es) 2019-01-14
ES3001509T3 (en) 2025-03-05
KR20210054598A (ko) 2021-05-13
US9572778B2 (en) 2017-02-21
US20230130866A1 (en) 2023-04-27
US20160375111A1 (en) 2016-12-29
EP3167897A1 (en) 2017-05-17
KR20180095738A (ko) 2018-08-27
EP4467160A2 (en) 2024-11-27
EP2480198B1 (en) 2016-03-09
DK2480198T3 (en) 2016-03-29
AU2010295299B2 (en) 2015-12-24
EP3834841B1 (en) 2023-05-17
PT3834841T (pt) 2023-06-19
US10238720B2 (en) 2019-03-26
ES2865250T3 (es) 2021-10-15
US20180207245A1 (en) 2018-07-26
US20200376098A1 (en) 2020-12-03
MX339205B (es) 2016-05-16
JP5819303B2 (ja) 2015-11-24
DK3834841T3 (da) 2023-06-06
HUE028688T2 (en) 2017-01-30
US8623352B2 (en) 2014-01-07
BR112012006283B1 (pt) 2022-03-15
US12178861B2 (en) 2024-12-31
US20190247475A1 (en) 2019-08-15
NZ598839A (en) 2014-03-28
FR24C1049I1 (fr) 2025-01-17
DK4218797T3 (da) 2024-12-09
CA2774556A1 (en) 2011-03-24
DK3167897T3 (da) 2021-04-19
EA201200519A1 (ru) 2012-09-28
US9351935B2 (en) 2016-05-31
WO2011035335A3 (en) 2011-12-01
KR101891646B1 (ko) 2018-08-27
US9937244B2 (en) 2018-04-10
CN102573792B (zh) 2014-10-15
FI4218797T3 (fi) 2024-12-07

Similar Documents

Publication Publication Date Title
MX2019000547A (es) Formulaciones de adamts13 liquidas y liofilizadas, estabilizadas.
ES2544967T3 (es) Formulación y método para la prevención y el tratamiento de las metástasis óseas o de otras enfermedades óseas
CL2013000018A1 (es) Compuestos derivados de indolizina , su procedimiento de preparacion; composicion farmaceutica; y uso en el tratamiento del cancer, entre otros.
CL2008000434A1 (es) Compuestos derivados de 2-amino-oxazolinas; proceso de obtencion; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como depresion, ansiedad, estres, trastorno bipolar, entre otros.
NI201100082A (es) Compuestos de isoindolina para uso en el tratamiento de cáncer.
UY32926A (es) Compuestos como antagonistas de los receptores de ácido lisofosfatídico
UY31816A (es) Agente para el tratamiento y/o prevención de una enfemedad autoinmune y para la formación de células t reguladoras
AR081681A1 (es) METODOS Y COMPOSICIONES PARA LA ADMINISTRACION INTRATECAL DE b-GALACTOCEREBROSIDASA
MX2013006040A (es) Antagonistas del receptor de acido lisofosfatidico y su uso en el tratamiento de fibrosis.
UY33029A (es) Antagonistas de espiro-oxindol de mdm2
UY32923A (es) Compuestos policíclicos como antagonistas del receptor de ácido lisofosfatídico
ECSP12011908A (es) OCTAHIDROPIRROLO[3,4-c]PIRROLOS DISUSTITUIDOS COMO
AR090465A1 (es) Formas solidas de un profarmaco de nucleotidos de tiofosforamidato
MX2015012502A (es) Inhibidores de proteina cinasa dependiente de adn.
CL2012001714A1 (es) Compuestos derivados de pirrol[3.4-b]piridin-5-ona, inhibidores de pi3k; composicion farmaceutica que los comprende; y uso para el tratamiento de enfermedades tales como alzheimer, epilepsia, esclerosis multiple, parkinson, entre otras.
UY33616A (es) Compuestos con estructura de imidazotriazinona
MX2013004061A (es) Analogos de ciclosporina.
GT200900328A (es) Derivados de bencimidazol
GT201400043A (es) Imidazopiridazinas sustituidas con amino
CO7180225A2 (es) Tratamientos de combinación para melanoma que comprenden la administración de cobimetinib y vemurafenib
IN2015DN02729A (es)
CO6551683A2 (es) Tratamiento para trastornos gastrointestinales
MX2012004078A (es) Compuestos y composiciones como moduladores de la actividad de gpr119.
CL2011000119A1 (es) Compuestos derivados de triazolo[4,3-a]piridina; procedimiento de preparacion; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer.
MX2013004062A (es) Analogos de ciclosporina.

Legal Events

Date Code Title Description
GB Transfer or rights

Owner name: TAKEDA PHARMACEUTICAL COMPANY LIMITED